WADA 2017 List of Prohibited Substances and Methods

By the present we would like to inform all players, team doctors and other basketball stakeholders that the World Anti-Doping Agency (WADA) has published the 2017 List of Prohibited Substances. 

The list will come into effect on 01 January 2017.

Under the FIBA Internal Regulations governing Anti-Doping, it is each player’s personal duty to ensure that no Prohibited Substance enters his or her body.
Therefore, it is essential that all players and support personnel review carefully the 2017 Prohibited List, particularly in cases where they intent to use supplements or medication.


Competing on an even playing field, where hard work, training and talent are the fundamental difference between winning and losing, holds a central place within the sporting ethos. The practice of trying to gain an unfair advantage through dishonest means is as old as sport itself. It remains a never-ending battle, but one that FIBA takes extremely seriously.

Since the 1980s, FIBA has regularly and in increasing numbers performed doping controls at its Championships. As a signatory of the WADA World Anti-Doping Code, first introduced in 2004, FIBA remains strongly committed to the fight against doping in basketball.


FIBA Anti-Doping activities cover the search for - and measures against- basketball players using banned substances and methods. Also, and just as importantly, they focus on actively promoting awareness of doping related issues, whether from a sporting or a health perspective.

This section contains all information related to FIBA’s anti-doping activities, whether from a player, team or medical staff point of view. It covers all regulations and procedures, outlined in the FIBA Internal Regulations governing Anti-Doping (Book 4) and aligned with the WADA Code, as well as providing practical information and details about FIBA’s Clean Game awareness programme.

FIBA's Responsibilities

FIBA is taking care of the following Anti-doping related tasks:

  • Organisation of doping controls for all FIBA competitions
  • Management of FIBA’s Out-of-Competition Testing System through its Registered Testing Pool
  • Results management in case of Adverse Analytical Findings (AAF)and review of national Anti-Doping Rule Violations (ADRV)
  • Management of Therapeutic Use Exemptions (TUEs)
  • Production and distribution of anti-doping material for doping controls and educational programmes
  • Cooperation and coordination with the Anti-Doping Organization involved in Basketball (National Federations, National Anti-Doping Organizations, professional leagues)

General testing principles

For doping controls FIBA makes the common distinction between In-Competition testing and Out-of-Competition testing.

In-Competition testing is currently defined as follows:

"In-Competition testing shall apply and is defined as any doping control of which the player is notified from 12 hours prior to an official game through to and including 4 hours after the game."

Out-of-Competition testing refers to all tests that are not defined as In-Competition. While it may apply to any basketball player of any league affiliated through its National Federation to FIBA, Out-of-Competition testing is mainly implemented through the Registered Testing Pool (RTP).

Please note that the above information is for basic informative purposes only. For the exact, legally-binding and most up-to-date regulations on Anti-Doping, always refer to the FIBA Internal Regulations governing Anti-Doping (Book 4).


FIBA Anti-Doping Testing Figures 2010-2014

In-Competition tests performed by FIBA 2010 2011 2012 2013 2014
World 208 52 104 52 310
Africa 32 56 32 88 40
Americas 6 38 8 42 30
Oceania 0 4 8 4 4
Asia 0 8 8 32 8
Europe 128 242 148 112 132
Euroleague Basketball/ EUroCup (ULEB) 92 92 96 156 124
TOTAL of In-Competition tests performed by FIBA 466 490 404 486 648
Number of In-Competition tests performed by the IOC - - 112 - -
Out-of-Competition tests performed by FIBA  2010 2011 2012 2013 2014
Out-of-Competition tests performed by FIBA   64 28 33 52 112
Out-of-Competition urine samples collected by FIBA 64 28 33 52 82
Out-of-Competition blood samples collected by FIBA 0 0 0 0 30
TOTAL NUMBER OF TESTS   530 518 549 538 760


TEST RESULTS 2010 2011 2012 2013 2014
Atypical Findings 2 3 0 7 6
Adverse Analytical Findings (AAFs) 10 13 16 1 3
AAFs closed as a result of a valid TUE 0 0 1 0 2
Anti-Doping Rule Violations among the number of AAFs 10 13 16 1 1
Other Anti-Doping Rule Violations 0 0 0 2 0